Trajectory of Viral RNA Load Among Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With COVID-19 Symptom Onset and Severity.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
04 01 2022
Historique:
entrez: 10 1 2022
pubmed: 11 1 2022
medline: 20 1 2022
Statut: epublish

Résumé

The SARS-CoV-2 viral trajectory has not been well characterized in incident infections. These data are needed to inform natural history, prevention practices, and therapeutic development. To characterize early SARS-CoV-2 viral RNA load (hereafter referred to as viral load) in individuals with incident infections in association with COVID-19 symptom onset and severity. This prospective cohort study was a secondary data analysis of a remotely conducted study that enrolled 829 asymptomatic community-based participants recently exposed (<96 hours) to persons with SARS-CoV-2 from 41 US states from March 31 to August 21, 2020. Two cohorts were studied: (1) participants who were SARS-CoV-2 negative at baseline and tested positive during study follow-up, and (2) participants who had 2 or more positive swabs during follow-up, regardless of the initial (baseline) swab result. Participants collected daily midturbinate swab samples for SARS-CoV-2 RNA detection and maintained symptom diaries for 14 days. Laboratory-confirmed SARS-CoV-2 infection. The observed SARS-CoV-2 viral load among incident infections was summarized, and piecewise linear mixed-effects models were used to estimate the characteristics of viral trajectories in association with COVID-19 symptom onset and severity. A total of 97 participants (55 women [57%]; median age, 37 years [IQR, 27-52 years]) developed incident infections during follow-up. Forty-two participants (43%) had viral shedding for 1 day (median peak viral load cycle threshold [Ct] value, 38.5 [95% CI, 38.3-39.0]), 18 (19%) for 2 to 6 days (median Ct value, 36.7 [95% CI, 30.2-38.1]), and 31 (32%) for 7 days or more (median Ct value, 18.3 [95% CI, 17.4-22.0]). The cycle threshold value has an inverse association with viral load. Six participants (6%) had 1 to 6 days of viral shedding with censored duration. The peak mean (SD) viral load was observed on day 3 of shedding (Ct value, 33.8 [95% CI, 31.9-35.6]). Based on the statistical models fitted to 129 participants (60 men [47%]; median age, 38 years [IQR, 25-54 years]) with 2 or more SARS-CoV-2-positive swab samples, persons reporting moderate or severe symptoms tended to have a higher peak mean viral load than those who were asymptomatic (Ct value, 23.3 [95% CI, 22.6-24.0] vs 30.7 [95% CI, 29.8-31.4]). Mild symptoms generally started within 1 day of peak viral load, and moderate or severe symptoms 2 days after peak viral load. All 535 sequenced samples detected the G614 variant (Wuhan strain). This cohort study suggests that having incident SARS-CoV-2 G614 infection was associated with a rapid viral load peak followed by slower decay. COVID-19 symptom onset generally coincided with peak viral load, which correlated positively with symptom severity. This longitudinal evaluation of the SARS-CoV-2 G614 with frequent molecular testing serves as a reference for comparing emergent viral lineages to inform clinical trial designs and public health strategies to contain the spread of the virus.

Identifiants

pubmed: 35006245
pii: 2787768
doi: 10.1001/jamanetworkopen.2021.42796
pmc: PMC8749477
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2142796

Subventions

Organisme : NIAID NIH HHS
ID : UM1 AI148684
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA213130
Pays : United States

Références

JAMA Netw Open. 2020 Jul 1;3(7):e2016382
pubmed: 32697321
Nature. 2021 Apr;592(7854):438-443
pubmed: 33690265
Infect Control Hosp Epidemiol. 2021 Jun;42(6):659-668
pubmed: 33077007
Antimicrob Agents Chemother. 2013 Dec;57(12):5820-9
pubmed: 24018260
JAMA Pediatr. 2021 Oct 1;175(10):e212025
pubmed: 34115094
J Med Virol. 2020 Nov;92(11):2286-2287
pubmed: 32347980
J Infect Dis. 2021 May 28;223(10):1666-1670
pubmed: 33580259
J Infect Dis. 2020 Jul 25;:
pubmed: 32710762
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32350048
N Engl J Med. 2020 Jul 9;383(2):185-187
pubmed: 32356944
Lancet Infect Dis. 2021 Jan;21(1):52-58
pubmed: 33058797
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
JAMA Pediatr. 2021 Jan 1;175(1):73-80
pubmed: 32857112
J Infect Dis. 2021 Feb 13;223(3):409-415
pubmed: 32692346
Science. 2020 Dec 11;370(6522):1339-1343
pubmed: 33159009
J Infect Dis. 2011 Aug 15;204(4):554-61
pubmed: 21791657
Int J Infect Dis. 2020 Jul;96:288-290
pubmed: 32437933
Lancet Infect Dis. 2020 Jun;20(6):656-657
pubmed: 32199493
Lancet Infect Dis. 2021 May;21(5):629-636
pubmed: 33545090
Cell Host Microbe. 2020 Jun 10;27(6):863-869
pubmed: 32464098
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
JAMA. 2021 Feb 16;325(7):632-644
pubmed: 33475701
PLoS Biol. 2021 Jul 12;19(7):e3001333
pubmed: 34252080
J Infect Dis. 2021 Jan 4;223(1):15-18
pubmed: 33020822
Sci Adv. 2020 Nov 20;6(47):
pubmed: 33097472
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
Lancet Microbe. 2021 Jan;2(1):e13-e22
pubmed: 33521734
Sci China Life Sci. 2020 May;63(5):706-711
pubmed: 32146694
N Engl J Med. 2021 Jan 21;384(3):238-251
pubmed: 33332778
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
J Clin Microbiol. 2020 Dec 17;59(1):
pubmed: 33046529
N Engl J Med. 2020 May 28;382(22):2081-2090
pubmed: 32329971
J Infect. 2020 Sep;81(3):357-371
pubmed: 32615199
JAMA Intern Med. 2020 Nov 1;180(11):1447-1452
pubmed: 32780793
Ann Intern Med. 2021 Mar;174(3):344-352
pubmed: 33284679
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Nat Rev Immunol. 2020 Aug;20(8):457-458
pubmed: 32636479
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Lancet Infect Dis. 2021 Sep;21(9):1246-1256
pubmed: 33857406
Emerg Infect Dis. 2021 Feb;27(2):352-359
pubmed: 33275874
Nature. 2021 May;593(7858):266-269
pubmed: 33767447
Clin Infect Dis. 2021 Nov 2;73(9):e2946-e2951
pubmed: 32840608
Clin Microbiol Infect. 2020 Nov;26(11):1556.e1-1556.e6
pubmed: 32653662

Auteurs

Helen C Stankiewicz Karita (HC)

Division of Allergy and Infectious Diseases, University of Washington, Seattle.

Tracy Q Dong (TQ)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Christine Johnston (C)

Division of Allergy and Infectious Diseases, University of Washington, Seattle.
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Department of Laboratory Medicine and Pathology, University of Washington, Seattle.

Kathleen M Neuzil (KM)

Department of Medicine, University of Maryland School of Medicine, Baltimore.

Michael K Paasche-Orlow (MK)

Department of Medicine, Boston University School of Medicine, Boston, Massachusetts.
Department of Medicine, Boston Medical Center, Boston, Massachusetts.

Patricia J Kissinger (PJ)

Department of Epidemiology, Tulane University, New Orleans, Louisiana.

Anna Bershteyn (A)

Department of Population Health, New York University Grossman School of Medicine, New York.

Lorna E Thorpe (LE)

Department of Population Health, New York University Grossman School of Medicine, New York.

Meagan Deming (M)

Department of Medicine, University of Maryland School of Medicine, Baltimore.

Angelica Kottkamp (A)

Department of Medicine, New York University Grossman School of Medicine, New York.

Miriam Laufer (M)

Department of Medicine, University of Maryland School of Medicine, Baltimore.
Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore.

Raphael J Landovitz (RJ)

Department of Medicine, University of California, Los Angeles, Los Angeles.

Alfred Luk (A)

Department of Medicine, Tulane University, New Orleans, Louisiana.

Risa Hoffman (R)

Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore.

Pavitra Roychoudhury (P)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Department of Laboratory Medicine and Pathology, University of Washington, Seattle.

Craig A Magaret (CA)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Department of Laboratory Medicine and Pathology, University of Washington, Seattle.

Alexander L Greninger (AL)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Department of Laboratory Medicine and Pathology, University of Washington, Seattle.

Meei-Li Huang (ML)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Keith R Jerome (KR)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Department of Laboratory Medicine and Pathology, University of Washington, Seattle.

Mark Wener (M)

Department of Laboratory Medicine and Pathology, University of Washington, Seattle.
Division of Rheumatology, University of Washington, Seattle.

Connie Celum (C)

Division of Allergy and Infectious Diseases, University of Washington, Seattle.
Department of Global Health, University of Washington, Seattle.
Department of Epidemiology, University of Washington, Seattle.

Helen Y Chu (HY)

Division of Allergy and Infectious Diseases, University of Washington, Seattle.
Department of Global Health, University of Washington, Seattle.
Department of Epidemiology, University of Washington, Seattle.

Jared M Baeten (JM)

Division of Allergy and Infectious Diseases, University of Washington, Seattle.
Department of Global Health, University of Washington, Seattle.
Department of Epidemiology, University of Washington, Seattle.

Anna Wald (A)

Division of Allergy and Infectious Diseases, University of Washington, Seattle.
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Department of Laboratory Medicine and Pathology, University of Washington, Seattle.
Department of Epidemiology, University of Washington, Seattle.

Ruanne V Barnabas (RV)

Division of Allergy and Infectious Diseases, University of Washington, Seattle.
Department of Global Health, University of Washington, Seattle.
Department of Epidemiology, University of Washington, Seattle.

Elizabeth R Brown (ER)

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Department of Biostatistics, University of Washington, Seattle.
Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH